Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
44 hedge funds and large institutions have $2.75M invested in Zynerba Pharmaceuticals, Inc in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 10 closing their positions.
12% less funds holding
Funds holding: 50 → 44 (-6)
35% less capital invested
Capital invested by funds: $4.23M → $2.75M (-$1.48M)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$46.7K |
| 2 |
VF
Virtu Financial
New York
|
+$17.1K |
| 3 |
HF
HRT Financial
New York
|
+$10.4K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$7.49K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$415K |
| 2 |
Renaissance Technologies
New York
|
-$143K |
| 3 |
D.E. Shaw & Co
New York
|
-$103K |
| 4 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$65.1K |
| 5 |
Millennium Management
New York
|
-$54.7K |
ZYNE Hedge Fund Activity: Q1 2023 in Review
44 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q1 2023, worth a combined $2.75M — down 35% from $4.23M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ZYNE and 5 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Wells Fargo, adding an estimated $46.7K. The largest seller was ETF Managers Group, cutting an estimated $415K.
- 44 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q1 2023, down from 50 in Q4 2022.
- Funds reported $2.75M of Zynerba Pharmaceuticals, Inc stock for Q1 2023, down 35% quarter-over-quarter.
- 5 funds opened new Zynerba Pharmaceuticals, Inc positions in Q1 2023 and 10 closed out, a net change of -5 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q1 2023 was Wells Fargo, an estimated $46.7K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q1 2023 was ETF Managers Group, an estimated $415K sold.
Based on aggregated 13F filings for Q1 2023.